RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Athira Pharma Stock

Athira Pharma Stocks 2024

Athira Pharma Stocks

38.02 M

Ticker

ATHA

ISIN

US04746L1044

WKN

A2QCFW

In 2024, Athira Pharma had 38.02 M outstanding stocks, a 0% change from the 38.02 M stocks in the previous year.

The Athira Pharma Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e38.02
2028e38.02
2027e38.02
2026e38.02
2025e38.02
2024e38.02
202338.02
202237.73
202136.92
202032.49
201930.82
201830.82

Athira Pharma shares outstanding

The number of shares was Athira Pharma in 2023 — This indicates how many shares 38.02 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Athira Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Athira Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Athira Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Athira Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Athira Pharma Aktienanalyse

What does Athira Pharma do?

Athira Pharma Inc. is a biopharmaceutical company founded in 2011 and based in Seattle, USA. The company focuses on the development of therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. The strategy of Athira is to develop therapies for the treatment of diseases of the central nervous system and the regeneration of tissues that have been damaged by injuries or aging, based on RNA-based technologies. This work is carried out by an experienced team of scientists and executives. Athira's business model is based on the goal of developing innovative and personalized drug therapies to prevent, slow down, or specifically treat diseases. The company pursues an evidence-based approach called "patient-centered approach." Athira aims to understand the cause of certain diseases and develop targeted therapies that aim to treat that cause. Athira's research and development area consists of three units: 1. Neurology: This division focuses on the development of therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. The company has already developed a drug candidate that is in an extended phase I/II clinical trial and shows potential for the treatment of Alzheimer's dementia. 2. Regeneration: The regeneration division mainly deals with the regeneration of nerve cells and tissues in the body. This area has the potential to develop therapies for the treatment of spinal cord injuries and degenerative diseases of the body. 3. Platform technology: Athira's platform technologies are based on RNA interference technology, which aims to experimentally silence genes. The platform technology aims to identify and validate cell-specific RNA targets that can address a wide range of diseases. Athira specializes in the research and development of innovative therapies with the goal of defeating diseases and improving patients' health. The company has achieved significant successes in recent years, positioning itself as an important player in the industry. The market for therapies for the treatment of neurodegenerative diseases offers immense opportunities and potentials as these diseases are expected to increase in the future due to the aging population. Athira sees itself well positioned to take on the challenges in the industry and continue to develop innovative solutions for the treatment of diseases. Athira Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Athira Pharma's Shares Outstanding

Athira Pharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Athira Pharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Athira Pharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Athira Pharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Athira Pharma stock

How many stocks are there of Athira Pharma?

The current number of stocks of Athira Pharma is 38.02 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Athira Pharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Athira Pharma evolved in recent years?

The number of shares of Athira Pharma has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Athira Pharma as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Athira Pharma?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Athira Pharma pay?

Over the past 12 months, Athira Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Athira Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Athira Pharma?

The current dividend yield of Athira Pharma is .

When does Athira Pharma pay dividends?

Athira Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Athira Pharma?

Athira Pharma paid dividends every year for the past 0 years.

What is the dividend of Athira Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Athira Pharma located?

Athira Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Athira Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Athira Pharma from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Athira Pharma pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Athira Pharma in the year 2023?

In the year 2023, Athira Pharma distributed 0 USD as dividends.

In which currency does Athira Pharma pay out the dividend?

The dividends of Athira Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Athira Pharma

Our stock analysis for Athira Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Athira Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.